3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Breast
3
Head & Neck
1
Gynecologic
1
Endocrine
1
Conditions
Breast Neoplasms
87
Neoplasms
11
Neoplasm Metastasis
10
Glioma
8
Ovarian Neoplasms
6
Melanoma
6
Glioblastoma
6
Squamous Cell Carcinoma of Head and Neck
5
Liposarcoma
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma
4
Recurrence
4
Medulloblastoma
4
Endometrial Neoplasms
4
Diffuse Intrinsic Pontine Glioma
4
Colorectal Neoplasms
4
Brain Neoplasms
4
Neuroblastoma
3
Neoplasms by Site
3
Lymphoma
3
Hereditary Sensory and Autonomic Neuropathies
3
Fallopian Tube Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Breast Diseases
3
Astrocytoma
3
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Endocrine Neoplasia Type 1
2
Interventions
exemestane
7
Trastuzumab
7
Anastrozole
7
Letrozole
6
Docetaxel
6
palbociclib
5
pyrotinib
4
entinostat
4
Fulvestrant
4
Cyclophosphamide
4
ribociclib
3
abemaciclib
3
Tamoxifen
3
Doxorubicin
3
pertuzumab
2
Sodium Chloride
2
Paclitaxel
2
Lapatinib
2
Gonadotropin-Releasing Hormone
2
Exercise
2
Everolimus
2
Epirubicin
2
Drug Evaluation
2
Capecitabine
2
Botulinum Toxins, Type A
2
Aromatase Inhibitors
2
AZD9833
2
trastuzumab deruxtecan
1
taxane
1
sacubitril and valsartan sodium hydrate drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Breast Diseases
×
ribociclib
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA